The Segment Anything Model (SAM) was fine-tuned on the EchoNet-Dynamic dataset and evaluated on external transthoracic echocardiography (TTE) and Point-of-Care Ultrasound (POCUS) datasets from CAMUS (University Hospital of St Etienne) and Mayo Clinic (99 patients: 58 TTE, 41 POCUS). Fine-tuned SAM was superior or comparable to MedSAM. The fine-tuned SAM also outperformed EchoNet and U-Net models, demonstrating strong generalization, especially on apical 2-chamber (A2C) images (fine-tuned SAM vs. EchoNet: CAMUS-A2C: DSC 0.891 {+/-} 0.040 vs. 0.752 {+/-} 0.196, p<0.0001) and POCUS (DSC 0.857 {+/-} 0.047 vs. 0.667 {+/-} 0.279, p<0.0001). Additionally, SAM-enhanced workflow reduced annotation time by 50% (11.6 {+/-} 4.5 sec vs. 5.7 {+/-} 1.7 sec, p<0.0001) while maintaining segmentation quality. We demonstrated an effective strategy for fine-tuning a vision foundation model for enhancing clinical workflow efficiency and supporting human-AI collaboration.

BackgroundAccurate left ventricular outflow tract obstruction (LVOTO) assessment is crucial for hypertrophic cardiomyopathy (HCM) management and prognosis. Traditional methods, requiring multiple views, Doppler, and provocation, is often infeasible, especially where resources are limited. This study aimed to develop and validate a deep learning (DL) model capable of predicting severe LVOTO in HCM patients using only the parasternal long-axis (PLAX) view from transthoracic echocardiography (TTE). MethodsA DL model was trained on PLAX videos extracted from TTE examinations (developmental dataset, n=1,007) to capture both morphological and dynamic motion features, generating a DL index for LVOTO (DLi-LVOTO, range 0-100). Performance was evaluated in an internal test dataset (ITDS, n=87) and externally validated in the distinct hospital dataset (DHDS, n=1,334) and the LVOTO reduction treatment dataset (n=156). ResultsThe model achieved high accuracy in detecting severe LVOTO (pressure gradient[&ge;] 50mmHg), with area under the receiver operating characteristics curve (AUROC) of 0.97 (95% confidence interval: 0.92-1.00) in ITDS and 0.93 (0.92-0.95) in DHDS. At a DLi-LVOTO threshold of 70, the model demonstrated a specificity of 97.3% and negative predictive value (NPV) of 96.1% in ITDS. In DHDS, a cutoff of 60 yielded a specificity of 94.6% and NPV of 95.5%. DLi-LVOTO also decreased significantly after surgical myectomy or Mavacamten treatment, correlating with reductions in peak pressure gradient (p<0.001 for all). ConclusionsOur DL-based approach predicts severe LVOTO using only the PLAX view from TTE, serving as a complementary tool, particularly in resource-limited settings or when Doppler is unavailable, and for monitoring treatment response.

BackgroundRetinal fundus images provide a noninvasive window into systemic health, offering opportunities for early detection of metabolic disorders such as metabolic syndrome (METS). ObjectiveThis study aimed to develop a deep learning model to predict METS from fundus images obtained during routine health checkups, leveraging a multi-task learning approach. MethodsWe retrospectively analyzed 5,000 fundus images from Japanese health checkup participants. Convolutional neural network (CNN) models were trained to classify METS status, incorporating fundus-specific data augmentation strategies and auxiliary regression tasks targeting clinical parameters such as abdominal circumference (AC). Model performance was evaluated using validation accuracy, test accuracy, and the area under the receiver operating characteristic curve (AUC). ResultsModels employing fundus-specific augmentation demonstrated more stable convergence and superior validation accuracy compared to general-purpose augmentation. Incorporating AC as an auxiliary task further enhanced performance across architectures. The final ensemble model with test-time augmentation achieved a test accuracy of 0.696 and an AUC of 0.73178. ConclusionCombining multi-task learning, fundus-specific data augmentation, and ensemble prediction substantially improves deep learning-based METS classification from fundus images. This approach may offer a practical, noninvasive screening tool for metabolic syndrome in general health checkup settings.

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/25326981v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): [email protected]@14e7b87org.highwire.dtl.DTLVardef@19005c4org.highwire.dtl.DTLVardef@6ac42f_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical AbstractC_FLOATNO C_FIG HighlightsO_LIA retrospective cohort of liver biopsies collected from over 20 healthcare centres has been assembled. C_LIO_LIThe cohort is characterized on the basis of collagen staining used for liver fibrosis assessment. C_LIO_LIA computational pipeline for the quantification of collagen from liver histology slides has been developed and applied to the described cohorts. C_LIO_LIUncertainty estimation is evaluated as a method to build trust in deep-learning based collagen predictions. C_LI The introduction of digital pathology has revolutionised the way in which histology-based measurements can support large, multi-centre studies. How-ever, pooling data from various centres often reveals significant differences in specimen quality, particularly regarding histological staining protocols. These variations present challenges in reliably quantifying features from stained tissue sections using image analysis. In this study, we investigate the statistical variation of measuring fibrosis across a liver cohort composed of four individual studies from 20 clinical sites across Europe and North America. In a first step, we apply colour consistency measurements to analyse staining variability across this diverse cohort. Subsequently, a learnt segmentation model is used to quantify the collagen proportionate area (CPA) and employed uncertainty mapping to evaluate the quality of the segmentations. Our analysis highlights a lack of standardisation in PicroSirius Red (PSR) staining practices, revealing significant variability in staining protocols across institutions. The deconvolution of the staining of the digitised slides identified the different numbers and types of counterstains used, leading to potentially incomparable results. Our analysis highlights the need for standardised staining protocols to ensure reliable collagen quantification in liver biopsies. The tools and methodologies presented here can be applied to perform slide colour quality control in digital pathology studies, thus enhancing the comparability and reproducibility of fibrosis assessment in the liver and other tissues.

PurposeAccurate cancer subtyping is crucial for effective treatment; however, it presents challenges due to overlapping morphology and variability among pathologists. Although deep learning (DL) methods have shown potential, their application to gigapixel whole slide images (WSIs) is often hindered by high computational demands and the need for efficient, context-aware feature aggregation. This study introduces LiteMIL, a computationally efficient transformer-based multiple instance learning (MIL) network combined with Phikon, a pathology-tuned self-supervised feature extractor, for robust and scalable cancer subtyping on WSIs. MethodsInitially, patches were extracted from TCGA-THYM dataset (242 WSIs, six subtypes) and subsequently fed in real-time to Phikon for feature extraction. To train MILs, features were arranged into uniform bags using a chunking strategy that maintains tissue context while increasing training data. LiteMIL utilizes a learnable query vector within an optimized multi-head attention module for effective feature aggregation. The models performance was evaluated against established MIL methods on the Thymic Dataset and three additional TCGA datasets (breast, lung, and kidney cancer). ResultsLiteMIL achieved 0.89 {+/-} 0.01 F1 score and 0.99 AUC on Thymic dataset, outperforming other MILs. LiteMIL demonstrated strong generalizability across the external datasets, scoring the best on breast and kidney cancer datasets. Compared to TransMIL, LiteMIL significantly reduces training time and GPU memory usage. Ablation studies confirmed the critical role of the learnable query and layer normalization in enhancing performance and stability. ConclusionLiteMIL offers a resource-efficient, robust solution. Its streamlined architecture, combined with the compact Phikon features, makes it suitable for integrating into routine histopathological workflows, particularly in resource-limited settings.

We developed and tested a deep-learning-based algorithm for the approximation of contrast agent dosage based on computed tomography (CT) scout images. We prospectively enrolled 817 patients undergoing clinically indicated CT imaging, predominantly of the thorax and/or abdomen. Patient weight was collected by study staff prior to the examination 1) with a weight scale and 2) as self-reported. Based on the scout images, we developed an EfficientNet convolutional neural network pipeline to estimate the optimal contrast agent dose based on patient weight and provide a browser-based user interface as a versatile open-source tool to account for different contrast agent compounds. We additionally analyzed the body-weight-informative CT features by synthesizing representative examples for different weights using in-context learning and dataset distillation. The cohort consisted of 533 thoracic, 70 abdominal and 229 thoracic-abdominal CT scout scans. Self-reported patient weight was statistically significantly lower than manual measurements (75.13 kg vs. 77.06 kg; p < 10-5, Wilcoxon signed-rank test). Our pipeline predicted patient weight with a mean absolute error of 3.90 {+/-} 0.20 kg (corresponding to a roughly 4.48 - 11.70 ml difference in contrast agent depending on the agent) in 5-fold cross-validation and is publicly available at https://tinyurl.com/ct-scout-weight. Interpretability analysis revealed that both larger anatomical shape and higher overall attenuation were predictive of body weight. Our open-source deep learning pipeline allows for the automatic estimation of accurate contrast agent dosing based on scout images in routine CT imaging studies. This approach has the potential to streamline contrast agent dosing workflows, improve efficiency, and enhance patient safety by providing quick and accurate weight estimates without additional measurements or reliance on potentially outdated records. The models performance may vary depending on patient positioning and scout image quality and the approach requires validation on larger patient cohorts and other clinical centers. Author SummaryAutomation of medical workflows using AI has the potential to increase reproducibility while saving costs and time. Here, we investigated automating the estimation of the required contrast agent dosage for CT examinations. We trained a deep neural network to predict the body weight from the initial 2D CT Scout images that are required prior to the actual CT examination. The predicted weight is then converted to a contrast agent dosage based on contrast-agent-specific conversion factors. To facilitate application in clinical routine, we developed a user-friendly browser-based user interface that allows clinicians to select a contrast agent or input a custom conversion factor to receive dosage suggestions, with local data processing in the browser. We also investigate what image characteristics predict body weight and find plausible relationships such as higher attenuation and larger anatomical shapes correlating with higher body weights. Our work goes beyond prior work by implementing a single model for a variety of anatomical regions, providing an accessible user interface and investigating the predictive characteristics of the images.

AO_SCPLOWBSTRACTC_SCPLOWThe quantification of the Ki-67 labeling index (LI) is critical for assessing tumor proliferation and prognosis in tumors, yet manual scoring remains a common practice. This study presents an automated workflow for Ki-67 scoring in whole slide images (WSIs) using an Apache Groovy code script for QuPath, complemented by a Python-based post-processing script, providing cell density maps and summary tables. The tissue and cell segmentation are performed using StarDist, a deep learning model, and adaptive thresholding to classify Ki-67 positive and negative nuclei. The pipeline was applied to a cohort of 632 pediatric brain tumor cases with 734 Ki-67-stained WSIs from the Childrens Brain Tumor Network. Medulloblastoma showed the highest Ki-67 LI (median: 19.84), followed by atypical teratoid rhabdoid tumor (median: 19.36). Moderate values were observed in brainstem glioma-diffuse intrinsic pontine glioma (median: 11.50), high-grade glioma (grades 3 & 4) (median: 9.50), and ependymoma (median: 5.88). Lower indices were found in meningioma (median: 1.84), while the lowest were seen in low-grade glioma (grades 1 & 2) (median: 0.85), dysembryoplastic neuroepithelial tumor (median: 0.63), and ganglioglioma (median: 0.50). The results aligned with the consensus of the oncology, demonstrating a significant correlation in Ki-67 LI across most of the tumor families/types, with high malignancy tumors showing the highest proliferation indices and lower malignancy tumors exhibiting lower Ki-67 LI. The automated approach facilitates the assessment of large amounts of Ki-67 WSIs in research settings.

BackgroundLung ultrasound (LUS) offers advantages over traditional imaging for diagnosing pulmonary conditions, with superior accuracy compared to chest X-ray and similar performance to CT at lower cost. Despite these benefits, widespread adoption is limited by operator dependency, moderate interrater reliability, and training requirements. Deep learning (DL) could potentially address these challenges, but development of effective algorithms is hindered by the scarcity of comprehensive image repositories with proper metadata. MethodsWe created an open-source dataset of LUS images derived a multi-center study involving N=226 adult patients presenting with respiratory symptoms to emergency departments between March 2020 and April 2022. Images were acquired using a standardized scanning protocol (12-zone or modified 8-zone) with various point-of-care ultrasound devices. Three blinded researchers independently analyzed each image following consensus guidelines, with disagreements adjudicated to provide definitive interpretations. Videos were pre-processed to remove identifiers, and frames were extracted and resized to 128x128 pixels. ResultsThe dataset contains 1,874 video clips comprising 303,977 frames. Half of the participants (50%) had COVID-19 pneumonia. Among all clips, 66% contained no abnormalities, 18% contained B-lines, 4.5% contained consolidations, 6.4% contained both B-lines and consolidations, and 5.2% had indeterminate findings. Pathological findings varied significantly by lung zone, with anterior zones more frequently normal and less likely to show consolidations compared to lateral and posterior zones. DiscussionThis dataset represents one of the largest annotated LUS repositories to date, including both COVID-19 and non-COVID-19 patients. The comprehensive metadata and expert interpretations enhance its utility for DL applications. Despite limitations including potential device-specific characteristics and COVID-19 predominance, this repository provides a valuable resource for developing AI tools to improve LUS acquisition and interpretation.

Predicting long-term functional outcomes for individuals with stroke is a significant challenge. Solving this challenge will open new opportunities for improving stroke management by informing acute interventions and guiding personalized rehabilitation strategies. The location of the stroke is a key predictor of outcomes, yet no clinically deployed tools incorporate lesion location information for outcome prognostication. This study responds to this critical need by introducing a fully automated, three-stage neuroimaging processing and machine learning pipeline that predicts personalized outcomes from clinical imaging in adult ischemic stroke patients. In the first stage, our system automatically processes raw DICOM inputs, registers the brain to a standard template, and uses deep learning models to segment the stroke lesion. In the second stage, lesion location and automatically derived network features are input into statistical models trained to predict long-term impairments from a large independent cohort of lesion patients. In the third stage, a structured PDF report is generated using a large language model that describes the strokes location, the arterial distribution, and personalized prognostic information. We demonstrate the viability of this approach in a proof-of-concept application predicting select cognitive outcomes in a stroke cohort. Brain-behavior models were pre-trained to predict chronic impairment on 28 different cognitive outcomes in a large cohort of patients with focal brain lesions (N=604). The automated pipeline used these models to predict outcomes from clinically acquired MRIs in an independent ischemic stroke cohort (N=153). Starting from raw clinical DICOM images, we show that our pipeline can generate outcome predictions for individual patients in less than 3 minutes with 96% concordance relative to methods requiring manual processing. We also show that prediction accuracy is enhanced using models that incorporate lesion location, lesion-associated network information, and demographics. Our results provide a strong proof-of-concept and lay the groundwork for developing imaging-based clinical tools for stroke outcome prognostication.

Accurate estimation of cerebral amyloid-{beta} (A{beta}) burden is critical for early detection and risk stratification in Alzheimers disease (AD). While A{beta} positron emission tomography (PET) remains the gold standard, its high cost, invasive nature and limited accessibility hinder broad clinical application. Blood-based biomarkers offer a non-invasive and cost-effective alternative, but their standalone predictive accuracy remains limited due to biological heterogeneity and limited reflection of central nervous system pathology. Here, we present a high-precision, multimodal prediction machine learning model that integrates plasma biomarkers, brain structural magnetic resonance imaging (sMRI) features, diffusion tensor imaging (DTI)-derived structural connectomes, and genetic risk profiles. The model was trained on 150 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI) and externally validated on 111 participants from the SILCODE cohort. Multimodal integration substantially improved A{beta} prediction, with R{superscript 2} increasing from 0.515 using plasma biomarkers alone to 0.637 when adding imaging and genetic features. These results highlight the potential of this multimodal machine learning approach as a scalable, non-invasive, and economically viable alternative to PET for estimating A{beta} burden.